Oncovita Welcomes Stéphane Altaba as New CEO
Oncovita, a forward-thinking biotechnology company, has announced the appointment of Dr. Stéphane Altaba as its new Chief Executive Officer. With a rich history of over 25 years in the pharmaceutical and biotechnology sectors, Altaba's extensive experience is expected to propel Oncovita's ambitions in therapeutic and prophylactic cancer vaccine development.
Leadership Experience and Vision
Dr. Stéphane Altaba's career is marked by significant achievements in research and development, particularly in biotechnological processes at Sanofi. He transitioned into corporate business development, gaining valuable insights while serving at both Sanofi and Nordic Pharma.
Key Senior Roles Experience
With a diverse background, Stéphane has held several senior management positions, including General Manager at Nordic Pharma Spa in Italy. His executive roles at various biotechnology companies, including Genomic Vision and LX Repair, highlight his capacity to lead complex organizations towards significant achievements.
Educational Background
Altaba's academic credentials are impressive as well. He earned a Ph.D. in bioproduction and completed a post-doctoral fellowship in Japan, solidifying his expertise. He also graduated from the esteemed ESCP Business School, further enhancing his strategic management capabilities.
New Era for Oncovita
Dr. Jean-François Le Bigot, the Executive Chairman, expressed excitement about Altaba joining the team. He emphasized that Altaba's proven track record in driving R&D initiatives, along with his extensive experience in licensing and collaboration, will be pivotal for Oncovita’s growth. This appointment signifies a transformative phase for Oncovita, where innovative cancer therapies are the priority.
Stéphane Altaba's Enthusiasm
In his statement, Stéphane Altaba reflected on his enthusiasm for joining Oncovita, attributing his decision to the remarkable talent within the team and the promising Measovir technology platform. He expressed his eagerness to contribute to the company's future, particularly in addressing significant healthcare needs in oncology.
Strategic Skills for Development
Altaba noted the complexities of leading a biotechnology firm at this stage, underlining the necessity of diverse skill sets including scientific and commercial expertise. His comprehensive understanding of these dynamics will facilitate Oncovita's mission to advance its vaccine candidates.
About Oncovita
Oncovita is dedicated to pioneering therapeutic and prophylactic vaccine research, focusing specifically on oncology and infectious diseases. Utilizing its proprietary Measovir technology platform, Oncovita seeks to transform the measles vaccine virus into effective therapeutic agents. Their unique methodology allows for the creation of high-impact immunotherapeutics tailored to tackle serious health challenges.
Recent Innovations and Funding
In alignment with their ongoing development efforts, Oncovita has made significant strides. Recently, the company was recognized as a laureate under the “Innovations in Biotherapies and Bioproduction” initiative, receiving substantial funding to propel their projects forward. A total of €8 million has been secured, bolstering research on their innovative MVdeltaC immunotherapeutic vaccine in oncology.
Frequently Asked Questions
What is the significance of Stéphane Altaba's appointment?
Stéphane Altaba's appointment is significant as it brings leadership with extensive experience that can drive Oncovita's projects and partnerships aimed at vaccine innovation.
What areas will Stéphane focus on as CEO?
As CEO, Stéphane will focus on enhancing R&D capabilities, managing licensing agreements, and addressing the unmet medical needs within oncology.
What technology does Oncovita specialize in?
Oncovita specializes in developing therapeutic and prophylactic vaccines using the proprietary Measovir technology platform, which modifies the measles virus genome.
How has Oncovita secured funding for its projects?
Oncovita has secured funding through the France 2030 investment plan, alongside private fundraising, totaling €8 million to support its ongoing vaccine development initiatives.
What is Oncovita's mission?
Oncovita’s mission is to advance its vaccine candidates from the preclinical stage to clinical proof of concept, targeting significant health challenges, particularly in oncology.
